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Background: Comparative analysis of expression profiles between early and late stage cancers can help to understand
cancer progression and metastasis mechanisms and to predict the clinical aggressiveness of cancer. The observed
stage-dependent expression changes can be explained by genetic and epigenetic alterations as well as transcription
dysregulation. Unlike genetic and epigenetic alterations, however, activity changes of transcription factors, generally
occurring at the post-transcriptional or post-translational level, are hard to detect and quantify.
Methods: Here we developed a statistical framework to infer the activity changes of transcription factors by
simultaneously taking into account the contributions of genetic and epigenetic alterations to mRNA
expression variations.
Results: Applied to kidney renal clear cell carcinoma (KIRC), the model underscored the role of methylation
as a significant contributor to stage-dependent expression alterations and identified key transcription factors
as potential drivers of cancer progression.
Conclusions: Integrating copy number, methylation, and transcription factor activity signatures to explain
stage-dependent expression alterations presented a precise and comprehensive view on the underlying
mechanisms during KIRC progression.Background
It is now widely accepted that cancer develops through a
series of stages [1]. In the early stage, cancer cells, con-
fined to a very limited area, are not invasive and meta-
static, whereas in the late stage, the cells, spreading to
distant sites in the body, are highly invasive and meta-
static. Comparative analysis of expression profiles be-
tween the early and late stages of cancers has identified
genes with stage-dependent expression alterations, most
of which have potential function in inducing and sup-
pressing cancer metastasis [2-6]. These findings help to* Correspondence: yu.shyr@vanderbilt.edu
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unless otherwise stated.get a better understanding of cancer progression and me-
tastasis and to predict the clinical aggressiveness of cancer.
However, the mechanisms that give rise to these expres-
sion alterations remain largely unknown.
An altered transcriptional regulatory network is one
major cause for the dysregulated expression during can-
cer progression, mainly due to activity changes in tran-
scription factors (TFs). The determination of TF activity
is difficult since it is generally regulated at the protein
level and thus undetectable by transcription profiling.
Much effort has been given to using reverse-engineering
techniques to infer TF activity, which is responsible for
differential expression across conditions [7-14]. These
techniques combine TF binding site information with ex-
pression profiles to distinguish active TFs from inactive
TFs. Recently, similar techniques have been extended and
applied to breast cancer and leukemia, helping us identifys is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain


















Figure 1 Flowchart of methods. We first identified stage-dependent
gene expression alterations, then evaluated the effect of
CNV/methylation on expression, and finally built a model to
infer stage-dependent activity changes of transcription factors
by combining the contributions of CNV/methylation.
Table 1 Characteristics of patients with RNA-seq, copy
number variation and methylation data for kidney renal
clear cell carcinoma
Stage I Stage IV
(n = 123) (n = 55)
Age in years
(mean ± standard deviation)
59.5 ± 13.1 62.8 ± 9.1
Gender, male; n (%) 73 (59.3%) 39 (70.9%)
Median follow-up in months
(minimum - maximum)
7.3 (0.03-14.8) 10.1 (0.03-14.9)
Number of deaths (%) 17 (13.8%) 43 (78.2%)
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ample, Cheng et al. [15] developed a method called BASE
to infer TF activity in tumor samples by integrating ex-
pression data and TF binding sites (positional weight
matrix from the TRANSFAC) and then investigated the
correlation between activity profiles and patient survival.
They found ATF/CREB and TAL1 were significantly cor-
related with breast cancer and acute myeloid leukemia pa-
tient survival, respectively. As another example, Zhu et al.
[16] proposed REACTIN to reveal the activity changes of
TFs between disease and normal samples. Combining ex-
pression data with ChIP-seq data from ENCODE [19],
REACTIN successfully detected activity changes of estro-
gen receptor between estrogen receptor-positive and
negative samples in breast cancer. However, the activity
changes of TFs are not the only factor responsible for ab-
errant transcriptional profiles. Other genetic and epigen-
etic alterations, such as DNA copy number or CpG island
methylation, also contribute to gene expression variations
[20]. Systematic modeling of transcriptional regulatory
programs, which accounts for gene expression alterations
beyond genetic and epigenetic contributions, will provide
a more accurate and powerful way to elucidate the rela-
tionship between TFs and disease.
Large-scale cancer genomics projects such as TCGA
(The Cancer Genome Atlas Research Network) are cur-
rently generating multiple layers of genomics data for
each tumor, including DNA copy number, methylation,
and mRNA expression, which provide a great opportun-
ity for systematic modeling of dysregulated transcription.
Here, we first identified differentially expressed genes
between 123 stage I and 55 stage IV kidney renal clear
cell carcinoma (KIRC) patients. Then, we demon-
strated contributions of copy number variation (CNV)
and methylation variation to gene expression alterations
by calculating the correlation of CNV/methylation with
expression of all genes and genes with stage-dependent al-
terations. Finally, we propose a multivariate regression
model to infer TF activity changes by associating gene ex-
pression outputs with TF binding events beyond the effect
of copy number and DNA methylation across KIRC stages
(Figure 1). Unlike the recent integrative method modeling
the general impact of copy number alterations on gene
expression changes [20], our approach models the gene-
specific contributions of both copy number and methyla-
tion to mRNA expression. The model shows improved
prediction performance, further demonstrates the role
of methylation as a significant contributor to stage-
dependent expression alterations, and identifies key
TFs as potential drivers of cancer progression. Dissecting
the effect of copy number, methylation and TF activity
changes on each individual gene with stage-dependent ex-
pression alteration gives a more comprehensive view of
underlying mechanisms.Methods
Data and preprocessing
CNV, DNA methylation, mRNA expression profiles and
clinical information for KIRC patients were downloaded
from the Broad Institute’s Genome Data Analysis Center
[21]. In total, 178 common samples with CNV, methyla-
tion and RNA-seq data were available, including from 123
stage I and 55 stage IV patients (Table 1). RSEM, based on
a general probabilistic model of maximum expectation,
was used to estimate gene expression abundance [22]. To
determine whether there were problematic samples, we
calculated the expression similarity between samples and
checked the percentage of necrotic cells, normal cells, and
tumor nuclei. Samples with different expression profiles
from others were composed of at least 85% tumor nuclei,
less than 5% normal cells, or less than 15% necrotic cells
(Additional file 1). Therefore, we kept all 178 samples
for downstream analysis. Pearson correlations between
mRNA expression and CNV/methylation were calculated.
Gene set enrichment analysis (GSEA) [23] was used
to determine functions significantly associated with high
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methylation. TF binding information was downloaded
from MsigDB, which strengthened the prediction of true
binding sites by considering the conservation across ge-
nomes [24]. After TFs with the same target sets were
combined, 206 TFs were left. Among 14,555 genes with
matched mRNA, methylation, and CNV data, 5,684 genes
had more than 5 interacting TFs.
Stage-dependent expression alterations
Limma [25] was applied to identify differentially expressed
genes between 123 stage I and 55 stage IV patients using
the following criteria: (1) fold change (FC) >2; and (2) false
discovery rate (FDR) <0.001 (Benjamini and Hochberg’s
multiple-test adjustment). Functional enrichment analysis
on the up-regulated and down-regulated genes was imple-
mented separately in Gene Ontology biological process
as well as KEGG (Kyoto Encyclopedia of Genes and
Genomes) pathways by WebGestalt [26,27]. Enrichment
P-values were generated by a hypergeometric test and ad-
justed by Benjamini and Hochberg’s multiple-test [28].
A multivariate regression model to connect copy number
variation, methylation and transcription factor activities
We associated gene expression outputs with TF bind-
ing events beyond the effect of copy numbers and
DNA methylation to infer TF activity changes across KIRC
stages. Assuming gene expression alterations were due to a
simple linear sum of activity changes in bound TFs and
copy numbers and DNA methylation variations, we built
a multivariate regression model where the dependent
variable is the log expression of genes, while independent
variables consist of copy numbers, DNA methylation and
predicted TF binding sites (Equation 1):




Sj ¼ 1; j∈stage IV0; j∈stage I Bf i ¼




where yij, Cij and Mij represent the log mRNA expres-
sion, copy number, and DNA methylation of gene i in
sample j, while Sj denotes the stage information of sam-
ple j and Bfi suggests whether TF f binds to gene i. The
regression coefficients βCNi and β
Me
i estimate the con-
tribution of copy numbers and methylation to mRNA
expression for gene i, while βf infers the activity change of
TF f in stage IV versus stage I. These regression coeffi-
cients were determined by minimizing the sum of squared







:The expression abundances of 5,684 genes across 178
samples were used to infer TF activity changes across
stages. That is, the number of data points n is 1,011,752
(5,684 × 178), while the number of regression coefficients
p is 11,574 (206 + 5,684 × 2). The solution is unique since
p < n. In addition, residuals look randomly scattered
around 0, and there is no evidence of a nonlinear pattern,
which suggests the linear regression model is a good fit to
the data (Additional file 2). We also used lasso and ridge
regression to model the expression changes and obtained
similar results (Additional file 3).
Results
Stage-dependent expression alterations
We identified 279 differentially expressed genes with
FC >2 and FDR <0.001. Of these, 178 (63.8%) had sig-
nificantly increased abundances, and 101 genes (36.2%)
had reduced expression in stage IV versus stage I cancer
(Additional file 4).
A clear difference between expression profiles of early
and late stage cancers was demonstrated in a heat map,
using the 279 differentially expressed genes (Figure 2A).
The up/down-regulated genes were further interpreted
in the context of Gene Ontology biological process as
well as KEGG pathways (Additional file 4). Cell cycle
(P = 1.9e-05), nuclear division (P = 1. 1e-07), system
development (P = 5.2e-05), cytokine-cytokine receptor
interaction (P = 3.85e-06), and p53 signaling pathway (P =
5.0e-04) are significantly enriched in the up-regulated
genes, while PPAR signaling pathway (P = 1.0e-04), ion
transport (P = 9.0e-04), transmembrane transport (P =
1.0e-04) and neuroactive ligand-receptor interaction
(P = 4.93e-11) are enriched in the down-regulated genes
(Figure 2B). Most of the pathways are involved in tumor
growth, invasion, and metastasis, which is consistent with
our existing knowledge of cancer progression. Notably,
cytokine and cytokine receptor interactions play crucial
roles in cancer development and progression [29,30]. Ten
genes involved in this pathway were up-regulated, includ-
ing CXCL13, XCL2, XCL1, IL2, AMH, LTB, INHBE,
TNFRSF18, CSF2 and IFNG. CXCL13 has been implicated
in the progression of breast cancer [31], and the addition
of lymphotactin (XCL1 and XCL2) has been shown to
stimulate ovarian cancer cell migration and proliferation
[32]. Cell cycle with 26 genes significantly up-regulated in
late stage cancer is also a well-known pathway involved in
tumor progression. Among these 26 genes, some have
already demonstrated their function in the progression of
other types of cancer - for example, CCNA1 [33,34] and
CDC20 [35]. In the p53 signaling pathway, RRM2, GTSE1,
BAI1 and CCNB2 were significantly overexpressed in
the late stage KIRC patients. The depletion of RRM2
has been reported to inhibit tumor growth in head and























Figure 2 Stage-dependent transcriptome signatures. (A) Hierarchical clustering of 123 stage I and 55 stage IV KIRC cancer patients based on
279 stage-dependent gene expression signatures. Red indicates upregulated and green indicates downregulated genes in stage IV. (B) Functions
enriched in upregulated genes. (C) Functions enriched in downregulated genes.
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cancers [38]. Their increased expression in the late stage
and the fact that they contribute to the progression and
invasion of other types of tumors indicates the important
roles of these genes in the progression of KIRC.
PPAR signaling pathways, significantly enriched in
down-regulated genes, are responsible for the regulation
of cellular events ranging from glucose and lipid homeo-
stasis to cell differentiation and apoptosis. Additionally,
emerging evidence indicates their anti-proliferative ac-
tions or tumor-promoting effects [39].
Contributions of copy number variation and methylation
to modulation of gene expression
To evaluate the contribution of CNV and methylation to
the modulation of stage-dependent gene expression alter-
ations, we measured the quantitative relationships be-
tween CNV/methylation and mRNA expression abundances
using Pearson correlation coefficients. A strong positive
correlation was observed between CNV and expressionwith a median correlation coefficient of 0.17, which is
consistent with the role of CNV in modulating gene ex-
pression (Figure 2A). Out of 13,508 genes, 10,989 (81.3%)
showed positive correlations, of which 5,994 (44.3%) had
significant correlations (P < 0.01) between CNV and ex-
pression, while only 2,519 (18.6%) showed negative corre-
lations, of which 227 (1.68%) had significant correlations
(Additional file 5). GSEA [23] showed that positive cor-
relations were represented by Golgi vesicle transport,
aminoacyl-tRNA biosynthesis, and proteasome, while
negative correlations were represented by cytokine meta-
bolic process and feeding behavior (Figure 3A). In con-
trast, genes with significant stage-dependent expression
alterations did not show strong positive correlations
between CNV and expression (median = 0.03). Those up/
down-regulated genes were not enriched in the positive
correlations (Figure 3A). Out of 178 differentially expressed
genes in late stage versus early stage cancer, only 46 genes
(25.8%) showed significant positive correlations. The correl-


















Figure 3 The effects of CNV and methylation on gene expression. (A) Ranked correlations of mRNA expression and CNV (top). The
locations of upregulated and downregulated genes and genes in the significantly associated functions are shown in the ranked list
(bottom). (B) The distributions of correlations between mRNA expression and CNV for upregulated genes, downregulated genes and all
genes. (C) Ranked correlations of mRNA expression and methylation (top). The locations of upregulated and downregulated genes and
genes in the significantly associated functions are shown in the ranked list (bottom). (D) The distributions of correlations between mRNA
and methylation for upregulated genes, downregulated genes and all genes.
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for other genes (Figure 3B), suggesting that CNV is not
a major factor in driving expression alterations during
KIRC cancer progression. However, CNV has import-
ant effects on expression changes of some cancer-related
genes. FOXM1 (FC = 1, FDR = 6.7e-06) and CDCA3 (FC =
1.2, FDR = 6.3e-07) are two representative genes over-
expressed in late stage cancer, which also had high cor-
relation coefficients between CNV and expression level
(R = 0.70 and R = 0.54, respectively).
A strong negative correlation was observed between
DNA methylation and expression with a median value
of -0.20, which is consistent with the role of methyla-
tion in repression of gene expression (Figure 3C). Out
of 13,982 genes, 12,629 (90.3%) showed negative correla-
tions, of which 6,552 (46.9%) were significant (P < 0.01),
while only 1,353 (9.68%) showed positive correlations, of
which 47 (0.33%) were significant (P < 0.01) (Additional
file 6). GSEA [23] showed that negative correlations wererepresented by primary immunodeficiency, G-protein-
coupled receptor signaling pathway, allograft rejection,
cell adhesion molecules (CAMs), and so on (Figure 3C).
Notably, genes down-regulated in late stage cancer
were enriched in negative correlations (FDR = 1.0e-05)
with a median value of -0.37. Among 101 down-regulated
genes, 92 (91.1%) showed negative correlations and
67 (66.3%) were significant. Compared with up-regulated
genes and other genes, DNA methylation was more nega-
tively correlated with expression abundances for down-
regulated genes (P < 2.2e-16; Figure 3D), suggesting that
methylation is a major cause leading to decreased ex-
pression abundance during cancer progression. More
interestingly, the most negatively correlated gene, AQP1
(R = -0.77, FC = -1.18, FDR = 1.54e-05), has been shown to
be related to tumor progression [40] and high AQP1 ex-
pression has been demonstrated to be associated with bet-
ter prognosis and improved overall survival outcome in
renal tumor patients [41].
Liu et al. Genome Medicine 2014, 6:117 Page 6 of 11
http://genomemedicine.com/content/6/12/117Expression alterations explained and transcription factor
activity changes inferred by the model
Since CNV and methylation modulate gene expression,
connecting these influential factors in the model is ex-
pected to give a comprehensive view of the underlying
mechanisms of stage-dependent expression alterations
and to provide more power for inferring transcriptional
programs driving tumor progression. Here we built a
multivariate regression model to infer activity changes of
TFs beyond copy number and methylation status varia-
tions using TF binding sites as features (see Methods).
We first assessed whether the integrative model could























Figure 4 The integrative model predicts expression alterations and T
observed and predicted gene expression for all genes (A) and differentially
than random (blue, P < 2.2e-16), while the integrative model combining TF
model (P < 2.2e-16). (C) Spearman correlations of observed and predict
TF-only, and the integrative model connecting TFs, CNV and methylation. (D)
FDR <0.001.samples. In a 10-fold cross-validation experiment on held
out patients and genes, we obtained a mean Spearman
rank correlation between predicted and observed gene ex-
pression abundance of 0.16 (median = 0.14). By contrast,
if we only consider transcriptional effect without tak-
ing genomic and epigenomic contributions into account
(the TF-only model), we obtained a mean Spearman rank
correlation of 0.03 (median = 0.04). Furthermore, if we
randomized gene expression abundances and trained the
integrative model, we obtained a mean Spearman rank
correlation just around 0 (mean = 0.0007, median = 0.001;
Figure 4A). For the 279 differentially expressed genes, our
integrative model predicted gene expression accuratelyator Target regulation Effect size FDR
Up 0.14 1.2e-13
Down -0.12 1.0e-08
2 Up 0.12 7.3e-08















-dependent TF activities changes
F activity changes. (A,B) The distribution of Spearman correlations of
expressed genes (B). The TF-only model (orange) is significantly better
s, CNV and methylation (red) is significantly better than the TF only
ed expression changes for differentially expressed genes using random,
Candidate regulators associated with KIRC stage with effect size >0.5 and
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0.35), while the TF-only model obtained a mean Spearman
correlation of 0.16 (median = 0.31) (Figure 4B; Pearson
correlation had similar results). We detected expression
changes in the late stage compared with the early stage
using the predicted expression abundances and found
that the predicted log expression changes across stages
were highly correlated with the observed ones (Spearman
correlation = 0.63). By contrast, the TF-only model ob-
tained a modest correlation between predicted log ex-
pression changes and the observed changes (Spearman
correlation = 0.56), and the random model failed to
predict stage-dependent gene expression changes with a
Spearman correlation around 0 (Figure 4C). The signifi-
cant improvement of the integrative model (P < 2.2e-16,
Kolmogorov-Smirnov test) further underscores the im-
portant role of CNV and methylation on stage-dependent
gene expression alterations.
Figure 4D summarizes the predicted dysregulation of
16 TFs in late stage cancer with FDR <0.001and effect
size >0.5 (Additional file 7). Many TFs are well-known
regulators in tumor progression and metastasis. The
most significant TF, GATA6, has been reported to pro-
mote colorectal cancer invasion [42], and its aberrant
expression is correlated with poor prognosis and liver
metastasis in colorectal cancer [43]. The second TF,
NFIL3, restricts expression of certain FOXO targets and
its expression in cancer is associated with patient sur-
vival [44]. A correlation of TCF12 overexpression with
colorectal cancer metastasis has also been suggested and
validated [45].
Among the 16 TFs, 5 (HLF, E2F7, HMGA1, REST, and
FOSB) were significantly changed at the mRNA expression
level (Additional file 4). Furthermore, the predicted target
regulation of TFs matched the direction of mRNA expres-
sion alterations and the function of TFs. For example,
REST was down-regulated in the late stage (log2(FC) = -0.45,
FDR= 0.005), which agreed with the predicted up-regulation
of its target genes since REST encodes a transcriptional
repressor. As another example, HMGA1, reported to func-
tion as a transcriptional mu enhancer, was up-regulated at
the mRNA expression level (log2(FC) = 0.72, FDR = 0.002),
and its target genes were consistently predicted to be up-
regulated. For some TFs with context-dependent function,
our prediction helped to determine their role in late stage
KIRC. For example, E2F7 mainly acts as a transcription re-
pressor [46,47] but activates expression of the VEGFA gene
when associated with HIF1A [48]. Here, E2F7 was up-
regulated in the late stage (log2(FC) = 0.95, FDR = 1.1e-04),
and its target genes were also up-regulated, which implies
that E2F7 might function as a transcriptional activator in
late stage KIRC.
The remaining 11 TFs did not show significant mRNA
expression changes in late stage versus early stage cancer.The main reason for this is that the ability of TFs is
generally modulated at the post-transcriptional and post-
translational levels, which will affect TF activity without
changing their mRNA abundance.
We further validated the stage-dependent TF activ-
ity changes using the GSE36895 dataset from the Gene
Expression Omnibus, which includes 29 KIRC tumors
with stage information. Despite a very small sample size
(five stage I and six stage IV patients), HLF was found to
be significantly down-regulated in the stage IV versus
stage I patients (log2(FC) = -1.94, P = 0.005; Figure 5A),
which is consistent with our results from the TCGA data-
set. Furthermore, the expression of HLF targets was more
significantly changed across stages than other non-targets
(P < 1e-06, one sided Kolmogorov-Smirnov test; Figure 5B).
These results support the stage-dependent activity changes
of HLF and also indicate HLF changes its activity through
mRNA expression alteration. Although the remaining 15
TFs did not show stage-dependent expression changes in
the GSE36895 dataset, the expression of their targets was
more likely to be changed in the late versus the early stages
than non-targets except for TCF12, REST and E2F7, which
provided indirect evidence of activity changes of these TFs
(Additional file 8).
Dissecting the role of transcription factor activity, copy
number variation and methylation
Among 117 differentially expressed genes with known
TF binding information, 81% (95) of gene expression al-
terations can be partially explained by changes in DNA
methylation, copy number, or TF activities (Additional
file 9). Methylation status changes were involved in alter-
ation of expression of 31 genes and TF activity changes in
81 genes, while CNV was the possible cause of altered ex-
pression in only 3 genes (CDCA3, INHB3, and COL7A1)
(Figures 6 and 7). These results further demonstrate
that methylation and TF activity changes had a major ef-
fect on stage-dependent expression alterations compared
with CNV.
Dissecting the specific roles of TF activity, CNV, and
methylation status changes on individual gene expression
alterations provides a more precise view of the underlying
regulatory mechanism (Figure 6). For example, CDCA3
was overexpressed in stage IV cancer (log2(FC) = 1.2, FDR
= 6.39e-07) and overexpression of CDCA3 has been re-
ported to be associated with oral cancer progression [49]
and prostate cancer [50], which suggests that CDCA3 also
plays an important role in KIRC progression and serves
as a potential therapeutic target for KIRC. Our model
revealed that the overexpression of CDCA3 was mainly
due to gene amplifications. XCL1 (log2(FC) = 1.33, FDR =
8.71e-05) and SRPX2 (log2(FC) = 1.45, FDR = 0.0002) have
been reported to enhance cancer progression and pro-









































Figure 5 Activity change of HLF in stage IV versus stage I in the GSE36895 dataset. (A) HLF is downregulated in stage IV versus stage I in
the GSE36895 dataset. (B) Expression of HLF targets is more likely to be changed compared with non-targets.
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cancer. In contrast, the overexpression of INHBE (log2
(FC) = 2.13, FDR = 7.90e-07) was caused by both gene amp-
lification and promoter demethylation. SLC14A1 and TEK,
underexpressed in the stage IV cancer (log2(FC) = -1.06,
FDR = 0.0007; log2(FC) = -1.09, FDR = 9.26e-06), were two
genes only regulated by GATA1. Consistently, previous
studies have demonstrated the down-regulation of these
two genes after GATA1 knockdown [52,53]. Since these
genes with stage-dependent expression alterations were
highly associated with tumor progression and metastasis,
the precise view of the underlying regulatory mechanism
would be helpful for guiding a future potentially successful
novel therapeutic target discovery and eventual use as a
patient stratification guide for cancer treatment.
Discussion
We present an integrative model connecting copy num-
ber, methylation, and TF activities to explain genome-
wide stage-dependent transcriptome signatures in cancer.Figure 6 The effect of CNV, methylation and TF activity on stage-depThe model predicts gene expression abundances accur-
ately and successfully identifies TFs responsible for stage-
dependent expression alterations. Dissecting the role of
CNV, altered methylation, and TF activity changes on in-
dividual gene expression alterations in late stage versus
early stage cancer provides new insight into the molecular
mechanisms driving tumor progression. To our know-
ledge, this is the first time that gene-specific contributions
of both CNV and methylation have been used to model
the transcriptional regulation effect.
An interesting observation is that genes down-regulated
in the late stage show higher inverse correlation between
DNA methylation and expression abundance than other
genes, which suggests down-regulated expression is partly
due to altered DNA methylation (see the ‘Contributions of
copy number variation and methylation to modulation of
gene expression’ section above). This finding is consistent
with previous studies that have reported accumulation
of DNA methylation changes across tumor stages and an















Figure 7 Venn diagram of genes whose stage-dependent expression alteration is regulated by TFs, CNV and DNA methylation.
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progression has been shown to be characterized by global
DNA hypomethylation in the early stage of carcinogenesis
and locus-specific DNA hypermethylation predomin-
antly in the late stage in the transgenic adenocarcinoma
of mouse prostate model (TRAMP) [55,62]. Our findings
also demonstrated the necessity of building an integrative
model to take into account all potential factors modulat-
ing gene expression and identify TFs associated with can-
cer progression in a more accurate and powerful way.
There are many opportunities to improve the integra-
tive method in future work. First, instead of using binary
TF binding profiles (binding/non-binding), incorporating
quantitative profiles restricted by chromatin-mediated
mechanisms, such as count of TF binding sites filtered by
DNase-seq data, will provide more precise and valuable
features. Second, TFs are multifunctional and typically
cooperate to activate or repress genes, exerting a more
complicated effect on transcriptional regulation than the
assumption of a simple linear sum of TF activity. Account-
ing for combinatorial regulation in the model will greatly
improve the method. Next, although this study focuses on
a dysregulated transcriptional program, the method can
be easily extended to incorporate other regulation. We
found some residuals that seem to be higher around the
fitted value of 0, leading to a slightly heavy tail of residue
distributions (Additional file 2; skewness = 0.12, kurtosis =
1.26). One possible reason is that there are missing variables
in the model. There are 22 genes with stage-dependent
expression alterations that cannot be explained by CNV,
altered methylation, or dysregulated transcription, which
suggests that other regulation programs responsible forexpression alterations in the late stage are not included in
the model. TFs are one potential source of missing vari-
ables since only 206 TFs with known binding targets are
included in the model compared with more than 1,000
TFs in humans [63]. MicroRNA (miRNA)-mediated post-
transcriptional regulation is another possible source.
Incorporating more TF binding information and miRNA
expression profiles with sequence-based miRNA target
information might further expand our knowledge of the
underlying mechanisms of cancer progression. Another
reason is that we only focus on stage-dependent changes
in the model, so other factors that lead to expression alter-
ations cannot be captured.
With the large-scale quantification of proteins becom-
ing possible, the integrative method can be modified to
model protein expression alterations beyond mRNA ex-
pression alterations to reveal potential translational or
post-translational regulators that lead to protein abun-
dance changes during cancer progression. Finally, this
method is broadly applicable to any cohort of cancer
patients for which copy number, methylation, and RNA
expression profiles are known. Analyzing dysregulated
transcriptional programs across all types of cancers simul-
taneously will provide the opportunity to explore whether
there are common or specific regulators underlying cancer
progression.
Conclusions
Integrating copy numbers, methylation, and TF activity
signatures to explain stage-dependent expression alter-
ations presents a precise and comprehensive view on the
underlying mechanisms during KIRC progression.
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